Revinova names Kiran Nataraj chief commercial officer

Revinova appointed Kiran Nataraj, Ph.D., as chief commercial officer to scale its AI agent platform for clinical trials. The hire brings commercial depth from Syneos Health and RQM+ as the company pushes adoption with sponsors, CROs and research sites.

Why it matters: - Revinova is trying to expand use of AI agents in clinical trials, where faster site activation and more consistent protocol training can affect study timelines and execution. - The appointment adds a commercial leader with deep life sciences sales experience as Revinova targets sponsors, CROs and research sites.

What happened: - Revinova named Kiran Nataraj, Ph.D., as chief commercial officer on October 5, 2026. - Nataraj will lead business development, sales and partnership strategy. - He will work with Revinova's product, clinical and customer success teams. - Revinova is based in Marlborough, Massachusetts.

The details: - Nataraj joins from RQM+, where he was senior director of business development. - He previously held the same role at Syneos Health and at AMRA Medical. - At AMRA Medical, he led sales of imaging biomarker and clinical data analytics solutions for trials in metabolic, neuromuscular and rare diseases. - Earlier in his career, Nataraj held senior sales roles at PerkinElmer and Olympus Scientific Solutions. - He began his career as a neuroscientist at Brandeis University. - Nataraj published peer-reviewed research in Nature, Neuron and the Journal of Neuroscience. - He holds a Ph.D. in biomedical engineering and neuroscience and an M.S. in biomedical engineering from The University of Akron. - Revinova's platform turns SOPs, protocols, training content and institutional knowledge into AI-powered learning experiences and AI agents. - The company says the clinical trial solution supports faster site activation, more consistent protocol training across global sites and ongoing learning reinforcement during the study lifecycle. - The platform combines a learning management system with agentic AI, runs on AWS Bedrock, and is SOC 2 Type II and HIPAA certified. - Revinova offers more information on its website. - Revinova also posted the announcement on LinkedIn.

Between the lines: - Revinova is pairing product development with a hire that understands how pharmaceutical, biotech and medtech buyers evaluate long-cycle technology purchases. - Nataraj's scientific background may help Revinova speak to both commercial and clinical audiences, which matters in a market where adoption often depends on trust and compliance. - The company is positioning AI as a way to turn static study documents into answers that are usable inside day-to-day trial workflows.

What's next: - Revinova will look to convert pilots into broader deployments across sponsor, CRO and site customers. - Nataraj is expected to help drive partnerships and commercial traction as clinical trial organizations look for faster activation and better protocol adherence.

The bottom line: - Revinova is betting that a seasoned life sciences sales leader can help turn its clinical trial AI platform into a faster-growing commercial product.